CD274 and non-small cell lung carcinoma: Drugs that inhibit PD-1 or PD-L1 (PD-(L)1 blockade) alone (IO) or in combination with platinum-doublet chemotherapy (Chemo-IO) are now standard-of-care therapeutic regimens in patients with advanced non-small cell lung cancer (NSCLC) without a driver alteration1–5.